Agile Therapeutics, Inc. (NASDAQ:AGRX) Q1 2020 Earnings Conference Call - Final Transcript
May 05, 2020 • 04:30 pm ET
Greetings, and welcome to the Agile Therapeutics First Quarter 2020 Financial Results Conference Call. [Operator Instructions].
It's now my pleasure to turn the call over to Matt Riley, Investor Relations for the company. Please go ahead, sir.
Matthew J. Riley
Hello, everyone, and welcome to today's conference call to discuss our first quarter financial results for 2020.
Before we start, let me remind you that today's call will include forward-looking statements based on our current expectations, including statements concerning our outlook for the fourth quarter and full year 2020, management's expectations for our future financial and operational performance, our business strategy and commercialization time line, our assessment of the size and value of the combined hormonal contraceptive market and the potential market share for Twirla, among other statements regarding our plans, prospects and expectations. Such statements represent our judgment as of today, are not promises or guarantees and may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Please refer to the filings with the SEC, which are available through the SEC's website at www.sec.gov as well as on our website for the information concerning risk factors that may affect the company. We undertake no obligation to update forward-looking statements, except as required by law. The information on today's call is not intended for promotional purposes and not sufficient for prescribing decisions. Joining me on today's call are Al Altomari, Agile Therapeutics' Chairman and Chief Executive Officer; and Dennis Reilly, Chief Financial Officer. Following our prepared remarks, we will open up the call to your questions.
Now let me turn the call over to Al.
Thank you, Matt. Good afternoon, everyone, and thank you for joining us. I want to welcome you to our first quarterly earnings call for Agile Therapeutics. Before we begin, I want to reflect on the times we find ourselves in. During this crisis, we are reminded on why we chose to be part of the health care industry, namely to help patients. For us at Agile, we think about women and their healthcare providers. It is the young woman looking to consider contraception who must have that important conversation on a telemedicine platform. It is the obstetrics patient who is going to have a checkup alone while her partner or loved one is waiting outside the office in the parking lot. We think about the 2,000-plus women who participate in the SECURE trial. We think about the 100 investigators and their teams that executed the SECURE trial. We have even a greater respect for the health care workers on the frontline, keeping us safe and caring for our sick.
But for a business like ours, now trying to build a company from our home offices, we owe an additional debt of gratitude to the other frontline, unsung heroes. It is our partner, Corium, that continues to execute on our manufacturing preparation. It is the computer techs, the postal carriers and the delivery drivers who make the sacrifices so we